ABVC (ABVC BioPharma) Total Long-Term Assets: $19.08 Mil (As of Mar. 2026)


ABVC ABVC BioPharma Inc ABVC
17 GF Score
Price $1.75
GF Value $0.87
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is ABVC BioPharma Total Long-Term Assets?

ABVC BioPharma ABVC +10.06% 17 Total Long-Term Assets is $19.08 Mil as of Mar. 2026. GuruFocus rates ABVC with a GF Score™ of 17/100 and a GF Value™ of $0.87 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. ABVC BioPharma's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $19.08 Mil.

ABVC BioPharma Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for ABVC BioPharma's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ABVC BioPharma Total Long-Term Assets Chart

ABVC BioPharma Annual Data
Trend Sep16 Sep17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.04 6.59 6.13 5.36 18.56

ABVC BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.41 13.47 17.10 18.56 19.08
ABVC
17GF Score
ABVC BioPharma Inc ABVC
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ABVC BioPharma Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $19.08 Mil mean?
ABVC BioPharma (ABVC) has a Total Long-Term Assets of $19.08 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on ABVC BioPharma and its competitors.
Is ABVC BioPharma's Total Long-Term Assets too high?
ABVC BioPharma's current Total Long-Term Assets is $19.08 Mil. Overall, ABVC BioPharma has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ABVC BioPharma's Total Long-Term Assets compare to GRCE and ELOX?
ABVC BioPharma's Total Long-Term Assets of $19.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on ABVC BioPharma and its competitors. ABVC BioPharma's current Total Long-Term Assets is $19.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABVC BioPharma stock overvalued right now?
Based on GuruFocus' analysis, ABVC BioPharma (ABVC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.75 — trading 101.1% above its estimated fair value. The current Total Long-Term Assets is $19.08 Mil. ABVC BioPharma's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For ABVC BioPharma (ABVC), the current Total Long-Term Assets is $19.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ABVC BioPharma (ABVC) Overvalued in 2026?

Based on GuruFocus' analysis, ABVC BioPharma stock appears to be overvalued. The current stock price of $1.75 is trading 101.1% above its estimated GF Value™ of $0.87. GuruFocus considers ABVC BioPharma to be Significantly Overvalued.

Key valuation signals for ABVC:

  • Total Long-Term Assets: $19.08 Mil
  • GF Value™: $0.87 vs. price of $1.75 (101.1% above fair value)
  • GF Score™: 17/100 with 1 warning sign

No single metric tells the full story. See the ABVC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ABVC BioPharma Business Description

Address 44370 Old Warm Springs Boulevard, Fremont, CA, USA, 94538
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
17GF Score

Get the complete analysis for ABVC

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.75
Price
$0.87
GF Value